Browsing Tag
Takeda Pharmaceutical Company Limited
6 posts
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.
How recombinant therapies are reshaping bleeding disorder treatment for children in 2025
Recombinant therapies are replacing plasma-derived treatments for pediatric bleeding disorders—see what’s driving this shift in 2025 and who’s leading.
Vonvendi gets green light for pediatric bleeding disorder care in FDA expansion
Find out how the FDA's expanded approval of Vonvendi opens new treatment avenues for children and adults with all types of von Willebrand disease.
Quebec lists Takeda’s FRUZAQLA for metastatic colorectal cancer under RAMQ formulary
Quebec approves public reimbursement of Takeda’s FRUZAQLA for metastatic colorectal cancer, expanding treatment access in Canada.
Lupin partners with Takeda to launch novel gastrointestinal drug Vonoprazan in India
In a significant development, Lupin Limited, a global pharmaceutical leader, announced a non-exclusive patent licence agreement with Takeda…